Reverse Convertible Bond 11,75 % Impfstoff Aktienanleihe The product related information contained herein is exclusively for information purposes only, intended for current investors or in case these products are displayed further to an individual search. The information does not constitute a recommendation or an offer to buy or an invitation to make a respective offer in relation to any of the products described herein.
Issue price100.00% Redemption price- Issue dateAug 04, 2021 Maturity dateAug 04, 2023
Name
11,75 % Impfstoff Aktienanleihe
ISIN / WKN
AT0000A2RZF6 / RC035L
Underlying
Worst of Basket
Capital protection amount
-
Participation factor
-
Cap
unlimited
Coupon p.a. in %
11.75%
Underlying price
-
Starting value
EUR 100.00
Strike
EUR 100.00
Denomination / nominal
EUR 1,000
Payed Coupons
11.75% on Aug 04, 2022
11.75% on Aug 04, 2023
About the term
Initial valuation date
Aug 03, 2021
Issue date
Aug 04, 2021
Final valuation date
Aug 01, 2023
Maturity date
Aug 04, 2023
Product classification
Investment Product without Capital Protection
Security type (eusipa Nr.)
Reverse Convertible Bond (1230)
Reverse Convertible Bond Type
Barrier Reverse Convertible Bonds
Underlying
Worst of Basket
Country / region of underlying
-
Suited market expectation
sideways, bullish
Observation barrier
Closing Price
Issue price
100.00%
Spread homogenised
-
Spread in %
-
Multiplier
-
Product currency
EUR
Underlying currency
-
Settlement method
Cash settlement / Physical delivery
Tax treatment
Capital Gains Tax / EU Withholding Tax
Public offer in
Austria, Germany, Italy, Hungary, Poland, Czech Republic, Slovakia, Bulgaria, Croatia, Romania, Slovenia
Listing
Vienna, Frankfurt, Stuttgart
Product info
Comments

The 11.75% Vaccination Reverse Convertible Bond is redeemed at 100% nominal value at the maturity date (Aug. 2023), provided that, during the observation period, the closing price of each of the two underlying shares (BioNTech SE, Moderna Inc.) always quoted above the barrier of 55% of the strike (daily observation). The interest amount of 11.75% is paid out annually, regardless of the performance of the underlying shares.

If the barrier of at least one of the two shares is violated and at least one of the underlying shares is quoted below its strike price, only the share with the worst performance is physically delivered. If both underlying shares quote at or above their strike at the final valuation date, the product is redeemed at 100% nominal value despite a barrier event.

The barrier has been touched by Moderna Inc on January 13, 2022.

Exchange Date Time Price Trading volume Nr. of trades Actions